Skip to content
Home/Companies/Biotech/Obsidian Therapeutics

Obsidian Therapeutics

Biotech·US·Active·2yr hold
Entry
2024
Hold
2yr
Status
Active

Who owns Obsidian Therapeutics?

Obsidian Therapeutics is currently owned by Novo Holdings through Novo Holdings Venture Investments (1999 vintage), since 2024.

Hand-verified · updated 2026-08-18

Novo Holdings
Investor
Novo Holdings
Novo Holdings Venture Investments · 1999 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive

More from Novo Holdings Venture Investments

Other portfolio companies in the same fund.

Claris Biotherapeutics
Active
BiotechUS· 2026
Windward Bio AG
Active
BiotechSwitzerland· 2026
AnaCardio
Active
BiotechSweden· 2025
Expedition Therapeutics
Active
BiotechUS· 2025
KIVU Bioscience
Active
BiotechUS· 2025
Asceneuron
Active
BiotechSwitzerland· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Obsidian Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Obsidian Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Obsidian Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue